Earnings release
Page 1
Exhibit 99.1 For immediate release November 3, 2026 AtriCure Reports Third Quarter 2026 Financial Results • Third Quarter 2026 worldwide revenue of $154.5 million, an increase of 15.0% year over year • Profitability expansion in the Third Quarter 2026, with net income of $4.1 million and adjusted EBITDA of $26.8 million MASON, Ohio, November 3, 2026 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2026 financial results. “Our third quarter results demonstrate the strength of our broad portfolio and our team’s disciplined execution,” said Michael Carrel, President and Chief Executive Officer. “Adoption of our innovative technologies is driving strong growth and expanding profitability, while the rapid progress of our BoxX-NoAF clinical trial reinforces our confidence in the opportunities ahead. We are well positioned to extend our leadership in cardiac surgery and post-operative pain management, creating lasting value for patients and our shareholders.” Third Quarter 2026 Financial Results Worldwide revenue for the third quarter 2026 was $154.5 million, an increase of 15.0% over third quarter 2025 revenue (15.1% on a constant currency basis). U.S. revenue was $128.0 million, an increase of $18.7 million or 17.1%, compared to the third quarter 2025. U.S. revenue growth was driven by sales of our cryoSPHERE MAX probe for post-operative pain management, EnCompass clamp in open ablation, and AtriClip FLEX-Mini and AtriClip PRO-Mini devices for appendage management. Minimally invasive ablation sales declined during the quarter from continued reduction in Hybrid procedures as physicians adopt PFA catheters to treat patients. International revenue increased $1.4 million or 5.8% (6.1% on a constant currency basis) to $26.4 million, with growth in all franchises. Gross profit for the third quarter 2026 was $119.4 million compared to $101.3 million for the third quarter 2025. Gross margin was 77.3% for the third quarter 2026, an increase of 180 basis points from the third quarter 2025, driven primarily by favorable product and geographic mix. Income from operations for the third quarter 2026 was $4.4 million, compared to $0.2 million for the third quarter 2025. Basic and diluted net income per share was $0.08 for the third quarter 2026, compared to basic and diluted net loss per share of $0.01 for the third quarter 2025. Adjusted EBITDA for the third quarter 2026 was $26.8 million, an increase of $9.0 million or 51% from the third quarter 2025. For the third quarter 2026, adjusted earnings per share was $0.18, compared to $0.01 adjusted loss per share for the third quarter 2025. Constant currency revenue, adjusted EBITDA and adjusted earnings (loss) per share are non-GAAP financial measures. We discuss these non-GAAP financial measures and provide reconciliations to GAAP measures later in this release. 2026 Financial Guidance Full year 2026 revenue is now projected to be approximately $606 million to $610 million, and management also projects full year 2026 adjusted EBITDA of approximately $91 million to $94 million. Full year 2026 net income per share is expected to be in the range of $0.21 to $0.27 and adjusted earnings per share of approximately $0.40 to $0.46. Additionally, management expects continued positive cash generation for 2026. Conference Call AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, November 3, 2026, to discuss third quarter 2026 financial results. To access the webcast, please visit the Investors page of AtriCure’s corporate website at https://ir.atricure.com/events-and- presentations/events. Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation. ® ™ ® ® ®
Page 2
About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure’s Isolator Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE and cryoXT probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure. Forward-Looking Statements Except for historical information, certain statements in this press release, including financial guidance and outlook, are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Such statements are covered by the Private Securities Litigation Reform Act safe harbor. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. These risks and uncertainties include, but are not limited to, the following: our estimate of the market for our products; the rate and degree of market acceptance of our products; negative clinical data; clinical trial enrollment, readouts and outcomes; competition from existing and new products and procedures, including the development of drugs or catheter-based technologies; our reliance on independent distributors to sell our products; inventory-related charges; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products and launching our products; impacts of rising healthcare costs; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; unfavorable publicity; the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make; disruptions to our manufacturing operations; the impact of tariffs or other restrictive trade measures; our failure to properly manage growth; disruptions of critical information systems or material breaches in the security of our systems; our ability to manage our intellectual property rights to provide meaningful protection; fluctuation of quarterly financial results; fluctuations in foreign currency exchange rates; reliance on third party manufacturers and suppliers; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 19, 2026, and our subsequent Quarterly Reports on Form 10-Q. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change, except as required by law. Use of Non-GAAP Financial Measures To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics. Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue for both management and investors. Adjusted EBITDA is calculated as net income (loss) before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, and non-recurring charges that are not reflective of the operational results of the Company’s core business and may affect comparability of results period-over-period. Non-recurring charges include acquisition costs, acquired-in-process research and development (IPR&D) and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and changes in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual ® ® ® ®
Page 3
operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)” later in this release. Adjusted earnings (loss) per share is a non-GAAP measure which calculates the net income (loss) per share before non-cash adjustments in fair value of contingent consideration liabilities, acquired IPR&D and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and debt extinguishment. The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. CONTACTS: Angie Wirick AtriCure, Inc. Chief Financial Officer (513) 755-5334 awirick@atricure.com Marissa Bych Gilmartin Group Investor Relations (415) 937-5402 marissa@gilmartinir.com
Page 4
ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, Except Per Share Amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 United States Revenue: Open ablation $ 43,003 $ 35,592 $ 122,968 $ 105,368 Minimally invasive ablation 5,389 7,428 17,806 23,747 Pain management 28,057 20,837 77,474 59,275 Appendage management 51,600 45,450 151,594 132,649 Total United States 128,049 109,307 369,842 321,039 International Revenue: Open ablation 11,178 10,852 31,937 30,196 Minimally invasive ablation 1,903 1,862 5,836 6,247 Pain management 2,440 2,080 6,810 5,902 Appendage management 10,880 10,168 34,878 30,644 Total International 26,401 24,962 79,461 72,989 Total revenue 154,450 134,269 449,303 394,028 Cost of revenue 35,100 32,937 102,013 98,586 Gross profit 119,350 101,332 347,290 295,442 Operating expenses: Research and development expenses 32,116 22,892 82,753 74,704 Selling, general and administrative expenses 82,881 78,232 249,993 232,676 Total operating expenses 114,997 101,124 332,746 307,380 Income (loss) from operations 4,353 208 14,544 (11,938) Other expense, net (336) (294) (707) (585) Income (loss) before income tax expense 4,017 (86) 13,837 (12,523) Income tax expense (benefit) (47) 181 710 681 Net income (loss) $ 4,064 $ (267) $ 13,127 $ (13,204) Basic net income (loss) per share $ 0.08 $ (0.01) $ 0.27 $ (0.28) Diluted net income (loss) per share $ 0.08 $ (0.01) $ 0.27 $ (0.28) Weighted average shares used in computing net income (loss)per share: Basic 48,893 47,920 48,633 47,680 Diluted 49,831 47,920 49,385 47,680
Page 5
ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands) (Unaudited) September 30,2026 December 31,2025 Assets Current assets: Cash and cash equivalents $ 187,031 $ 167,428 Accounts receivable, net 76,128 66,653 Inventories 87,310 78,492 Prepaid and other current assets 12,921 9,944 Total current assets 363,390 322,517 Property and equipment, net 66,667 39,123 Operating lease right-of-use assets 5,711 6,868 Goodwill and intangible assets, net 275,656 282,807 Other noncurrent assets 6,112 2,864 Total Assets $ 717,536 $ 654,179 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued liabilities $ 80,245 $ 78,399 Other current liabilities 3,727 3,121 Total current liabilities 83,972 81,520 Long-term debt 61,000 61,865 Finance and operating lease liabilities 32,105 11,516 Other noncurrent liabilities 7,235 7,343 Total Liabilities 184,312 162,244 Stockholders' Equity: Common stock 51 50 Additional paid-in capital 933,234 904,522 Accumulated other comprehensive income 15 566 Accumulated deficit (400,076) (413,203) Total Stockholders' Equity 533,224 491,935 Total Liabilities and Stockholders' Equity $ 717,536 $ 654,179
Page 6
ATRICURE, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS (In Thousands) (Unaudited) Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA) Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Net income (loss), as reported $ 4,064 $ (267) $ 13,127 $ (13,204) Income tax expense (benefit) (47) 181 710 681 Other expense, net 336 294 707 585 Depreciation and amortization expense 5,474 5,169 16,055 15,424 Share-based compensation expense 12,478 12,424 36,064 33,425 Acquired in-process research & development expense 4,500 — 4,500 5,000 Non-GAAP adjusted income (adjusted EBITDA) $ 26,805 $ 17,801 $ 71,163 $ 41,911 Reconciliation of Non-GAAP Adjusted Earnings (Loss) Per Share Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Net income (loss), as reported $ 4,064 $ (267) $ 13,127 $ (13,204) Acquired in-process research & development expense 4,500 — 4,500 5,000 Non-GAAP adjusted net income (loss) $ 8,564 $ (267) $ 17,627 $ (8,204) Adjusted earnings (loss) per share $ 0.18 $ (0.01) $ 0.36 $ (0.17) Adjusted earnings (loss) per diluted share $ 0.17 $ (0.01) $ 0.36 $ (0.17) Weighted average shares used in computing adjusted earnings(loss) per share Basic 48,893 47,920 48,633 47,680 Diluted 49,831 47,920 49,385 47,680